Literature DB >> 26846102

Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells.

Kuan Cao1,2, Hui Gong2,3, Zhichao Qiu2,3, Quan Wen1, Bin Zhang1, Tianjin Tang4,2, Xinyu Zhou1,2, Tong Cao4,2, Bin Wang4,2, Hengliang Shi5,6, Renhao Wang7.   

Abstract

Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is the most widespread type of liver cancer. However, the underlying mechanism of HCC tumorigenesis is very intricate and HBV-encoded X protein (HBx) has been reported to play a key role in this process. It has been reported that HBx up-regulates the transcription of ErbB3. However, it remains unclear whether HBx can regulate ErbB3 expression at post-translational modification level. In this study, we showed that HBx interacts with ubiquitin ligase Nrdp1 (neuregulin receptor degradation protein 1) and decreases its stability, which results in the up-regulation of ErbB3 and promotion of HCC cells. Moreover, the expression of ErbB3 was almost undetectable in normal liver tissues but was relative abundant in HCC tissues, and the level of ErbB3 and Nrdp1 significantly showed a negative correlation in HCC tissues. Taken together, these findings suggest that HBx promotes the progression of HCC by decreasing the stability of Nrdp1, which results in up-regulation of ErbB3, suggesting that ErbB3 may be a target for HCC therapy.

Entities:  

Keywords:  ErbB3; HBV; HBx; HCC; Nrdp1

Mesh:

Substances:

Year:  2016        PMID: 26846102     DOI: 10.1007/s13277-016-4936-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis.

Authors:  Shirine Benhenda; Delphine Cougot; Marie-Annick Buendia; Christine Neuveut
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

2.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

3.  The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.

Authors:  Annemarie Losert; Daniela Lötsch; Andreas Lackner; Herwig Koppensteiner; Barbara Peter-Vörösmarty; Elisabeth Steiner; Klaus Holzmann; Thomas Grunt; Katharina Schmid; Brigitte Marian; Bettina Grasl-Kraupp; Rolf Schulte-Hermann; Georg Krupitza; Walter Berger; Michael Grusch
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

4.  Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27.

Authors:  Hang Lu; Hua Li; Dong Mao; Zhitu Zhu; Hongzhi Sun
Journal:  Tumour Biol       Date:  2014-05-28

5.  Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.

Authors:  Lily Yen; Zhongwei Cao; Xiuli Wu; Ellen R Q Ingalla; Colin Baron; Lawrence J T Young; Jeffrey P Gregg; Robert D Cardiff; Alexander D Borowsky; Colleen Sweeney; Kermit L Carraway
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

6.  Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis.

Authors:  Sen-Yung Hsieh; Jung-Ru He; Ming-Chin Yu; Wei-Chen Lee; Tse-Chin Chen; Shao-Jung Lo; Rabindranath Bera; Chang-Mung Sung; Cheng-Tang Chiu
Journal:  J Proteome Res       Date:  2011-09-15       Impact factor: 4.466

7.  An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels.

Authors:  A John Diamonti; Pamela M Guy; Caryn Ivanof; Karen Wong; Colleen Sweeney; Kermit L Carraway
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 8.  Targeting the human EGFR family in esophagogastric cancer.

Authors:  Alicia Okines; David Cunningham; Ian Chau
Journal:  Nat Rev Clin Oncol       Date:  2011-04-05       Impact factor: 66.675

Review 9.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

10.  Differentially profiling the low-expression transcriptomes of human hepatoma using a novel SSH/microarray approach.

Authors:  Yi-Shin Pan; Yun-Shien Lee; Yung-Lin Lee; Wei-Chen Lee; Sen-Yung Hsieh
Journal:  BMC Genomics       Date:  2006-05-31       Impact factor: 3.969

View more
  6 in total

1.  miR‑148a‑3p regulates alcoholic liver fibrosis through targeting ERBB3.

Authors:  Jie Xiong; Jianbo Ni; Congying Chen; Kezhou Wang
Journal:  Int J Mol Med       Date:  2020-06-23       Impact factor: 4.101

2.  Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma.

Authors:  Xian Shao; Qian Lu; Gang Wang; Wei Huang; Linlin Yang; Zhong Chen
Journal:  Onco Targets Ther       Date:  2018-08-17       Impact factor: 4.147

Review 3.  The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis.

Authors:  Fanyun Kong; Hongjuan You; Delong Kong; Kuiyang Zheng; Renxian Tang
Journal:  Virol J       Date:  2019-05-30       Impact factor: 4.099

4.  MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3.

Authors:  Guoyun Li; Wei Zhang; Li Gong; Xiaoping Huang
Journal:  Oncol Res       Date:  2017-08-11       Impact factor: 5.574

5.  Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Authors:  Corina Buta; Eva Benabou; Marie Lequoy; Hélène Régnault; Dominique Wendum; Fatiha Meratbene; Hamza Chettouh; Lynda Aoudjehane; Filomena Conti; Yves Chrétien; Olivier Scatton; Olivier Rosmorduc; Françoise Praz; Laetitia Fartoux; Christèle Desbois-Mouthon
Journal:  J Exp Clin Cancer Res       Date:  2016-08-11

6.  TSG101 promotes the proliferation, migration and invasion of hepatocellular carcinoma cells by regulating the PEG10.

Authors:  Zhiyi Liu; Zilu Tian; Kuan Cao; Bin Zhang; Quan Wen; Xinyu Zhou; Weibin Yang; Tao Wang; Hengliang Shi; Renhao Wang
Journal:  J Cell Mol Med       Date:  2018-11-18       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.